This invention identifies a novel non-coding RNA (ncRNA) transcript as a potential diagnostic and prognostic marker for lung adenocarcinoma. Furthermore, inhibitors of this novel ncRNA might hold therapeutic potential.
Lung cancer is potentially curable when discovered early but patients rarely exhibit early clinical symptoms. Identification of genetic alterations in asymptomatic individuals may therefore considerably improve their prognostic. Currently only 25-35% of lung adenocarcinoma patients have recognizable genetic alterations and related targets for personalized medicine. None of these known genetic alterations are clinically proven as early diagnostic markers in lung adenocarcinoma. Therefore, there is a great need for new reliable method of detecting early stage lung adenocarcinoma and improving clinical outcomes based on individual personalized treatment.
This novel invention provides the following advantage:
- Potential target for lung adenocarcinoma personalized therapies (in vitro data)
Scientists at the University of California, San Francisco have identified a novel biomarker for lung adenocarcinoma. The biomarker has been identified comparing thoracic malignancies to matched normal tissues using inventors’ in-house genetic methods. The biomarker signature was found to be dominant and potentially specific to this disorder and could be used for early detection of asymptomatic patients and guide therapy with more accuracy.
To develop and commercialize this technology.
Preclinical
Under NDA/CDA
Diagnostic, Therapeutic target, Lung Adenocarcinoma, Biomarker